On Thursday, Elevation Oncology, Inc. ELEV elected to discontinue the event of EO-3021, a Claudin 18.2 antibody-drug conjugate (ADC).
The corporate was creating a remedy for superior, unresectable or metastatic gastric and gastroesophageal junction cancers.
The choice got here because of disappointing information from the dose escalation and growth phases of Elevation Oncology’s Part 1 trial.
Therapy with EO-3021 as monotherapy demonstrated an goal response price of twenty-two.2% (1 confirmed full response and seven confirmed partial responses) and a illness management price of 72.2% amongst 36 evaluable sufferers with gastric or GEJ most cancers and Claudin 18.2 in ≥20% of tumor cells at IHC 2+/3+.
Additionally Learn: Elevation Oncology: Promising Most cancers Therapies Earn Analyst Reward
Within the security evaluation of all enrolled sufferers (n=85), remedy with EO-3021 was noticed to be typically well-tolerated.
Therapy with EO-3021 didn’t meet the corporate’s “bar for fulfillment,” stated Elevation Oncology CEO Joseph Ferra.
Elevation Oncology will proceed to advance EO-1022, a HER3 ADC for sufferers with HER3-expressing stable tumors. The corporate plans to file an Investigational New Drug (IND) software in 2026.
In parallel, the corporate is initiating a course of to judge strategic choices to maximise shareholder worth.
Elevation Oncology is implementing a workforce discount of roughly 70%. The layoffs will end in complete money funds and prices of roughly $3 million.
As a part of this discount, Elevation Oncology’s Chief Medical Officer, Valerie Malyvanh Jansen, will step down, efficient March 31.
Elevation Oncology expects that its money, money equivalents, and marketable securities of $93.2 million as of Dec. 31, can be enough to fund its operations into the second half of 2026.
Value Motion: ELEV inventory is down 47.1% at 25 cents on the final examine Thursday.
Learn Subsequent:
Momentum6.88
Progress–
High quality–
Worth–
Market Information and Information delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
